Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results

MC Dubinsky; PM Irving; XY Li; S Howaldt; Juris Pokrotnieks; K Krueger; J Laskowski; T Lissoos; J Milata; N Morris; V Arora; C Milch; BE Sands; E Dhesi

doi:10.1136/gutjnl-2023-BSG.144

Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results

MC Dubinsky, PM Irving, XY Li, S Howaldt, Juris Pokrotnieks, K Krueger, J Laskowski, T Lissoos, J Milata, N Morris, V Arora, C Milch, BE Sands, E Dhesi

Rīga Stradiņš University

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	A86-A87
Number of pages	2
Journal	Gut
Volume	72
Issue number	Suppl.2
DOIs	https://doi.org/10.1136/gutjnl-2023-BSG.144
Publication status	Published - Jun 2023
Event	Annual Meeting of the British Society of Gastroenterology - Liverpool, United Kingdom Duration: 19 Jun 2023 → 22 Jun 2023 https://www.medflixs.com/en/conferences/the-british-society-of-gastroenterology-live-bsg-live-2023

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1136/gutjnl-2023-BSG.144

Cite this

Dubinsky, MC., Irving, PM., Li, XY., Howaldt, S., Pokrotnieks, J., Krueger, K., Laskowski, J., Lissoos, T., Milata, J., Morris, N., Arora, V., Milch, C., Sands, BE., & Dhesi, E. (2023). Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results. Gut, 72(Suppl.2), A86-A87. https://doi.org/10.1136/gutjnl-2023-BSG.144

@article{bdf611a854db4d27bda1d96c03878a56,

title = "Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results",

author = "MC Dubinsky and PM Irving and XY Li and S Howaldt and Juris Pokrotnieks and K Krueger and J Laskowski and T Lissoos and J Milata and N Morris and V Arora and C Milch and BE Sands and E Dhesi",

year = "2023",

month = jun,

doi = "10.1136/gutjnl-2023-BSG.144",

language = "English",

volume = "72",

pages = "A86--A87",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "Suppl.2",

note = "Annual Meeting of the British Society of Gastroenterology , BSG LIVE{\textquoteright}22 ; Conference date: 19-06-2023 Through 22-06-2023",

url = "https://www.medflixs.com/en/conferences/the-british-society-of-gastroenterology-live-bsg-live-2023",

}

Dubinsky, MC, Irving, PM, Li, XY, Howaldt, S, Pokrotnieks, J, Krueger, K, Laskowski, J, Lissoos, T, Milata, J, Morris, N, Arora, V, Milch, C, Sands, BE & Dhesi, E 2023, 'Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results', Gut, vol. 72, no. Suppl.2, pp. A86-A87. https://doi.org/10.1136/gutjnl-2023-BSG.144

TY - JOUR

T1 - Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis

T2 - Annual Meeting of the British Society of Gastroenterology

AU - Dubinsky, MC

AU - Irving, PM

AU - Li, XY

AU - Howaldt, S

AU - Pokrotnieks, Juris

AU - Krueger, K

AU - Laskowski, J

AU - Lissoos, T

AU - Milata, J

AU - Morris, N

AU - Arora, V

AU - Milch, C

AU - Sands, BE

AU - Dhesi, E

PY - 2023/6

Y1 - 2023/6

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:001053334700144

U2 - 10.1136/gutjnl-2023-BSG.144

DO - 10.1136/gutjnl-2023-BSG.144

M3 - Meeting Abstract

SN - 0017-5749

VL - 72

SP - A86-A87

JO - Gut

JF - Gut

IS - Suppl.2

Y2 - 19 June 2023 through 22 June 2023

ER -

Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this